Related Experiment Video
Updated: Jul 28, 2025
07:38
Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
Published on: May 10, 2024
678
Delayed euDKA Associated With Dapagliflozin After Pancreatitis
Gao Wu1, Shuxie Wu2, Jin Tang3
1Department of Pharmacy, First Affiliated Hospital of Naval Military Medical University, Shanghai, China.
Clinical Therapeutics
|May 29, 2023
Summary
Euglycemic diabetic ketoacidosis (euDKA) is a rare risk of SGLT2 inhibitors. Acute pancreatitis may predispose patients with type 2 diabetes to this serious condition.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used for type 2 diabetes mellitus (T2DM).
- Euglycemic diabetic ketoacidosis (euDKA) is a rare but serious adverse effect associated with SGLT2 inhibitor use.
Observation:
- A 51-year-old male with T2DM on dapagliflozin developed delayed euDKA seven days after recovering from acute pancreatitis.
- The patient's pancreatitis was considered a potential contributing factor to the euDKA development.
Findings:
- Discontinuation of oral hypoglycemic agents led to clinical improvement.
- Stress factors such as acute illness (e.g., pancreatitis) may increase the risk of SGLT2 inhibitor-associated euDKA.
Implications:
- Clinicians should be aware of the potential for SGLT2 inhibitor-associated euDKA in T2DM patients experiencing acute illnesses like pancreatitis.
- Recognizing predisposing factors is crucial for managing T2DM patients on SGLT2 inhibitors.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
01:24Glucagon-like Receptor Agonists
372
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
372
01:30Acute Pancreatitis II: Clinical Manifestations and Management
159
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
159
01:06Oral Hypoglycemic Agents: Glinides
190
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
190
01:24Chronic Pancreatitis I: Introduction
117
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
117
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
220
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
220